Pediatric Blood & Cancer · 2021 · 13 citations · 26 references
MedicineHematologyImmunologyCell TherapyStem Cell TransplantationTransplant ImmunologyConditioning RegimensDonor MatchingGraft-versus-host DiseaseHematopoietic Stem Cell TransplantationTransplant-related ToxicitiesCyclophosphamide-based ConditioningHematopoietic Stem Cell Transplant ConditioningHost Immune SuppressionMatched Unrelated Donor TransplantationPost-transplant CyclophosphamideTransplant Conditioning ToxicityTransplantation Outcome AssessmentUnrelated Donation
Hematopoietic stem cell transplant (HSCT) is currently the only curative option for thalassemia major (TM) and sickle cell disease (SCD). We report our experience of using pretransplant immune suppression (PTIS), augmented Johns Hopkins conditioning, and posttransplant cyclophosphamide (PTCy) as graft-versus-host disease (GvHD) prophylaxis for matched unrelated donor (MUD) transplant in TM/SCD. At a median follow-up of 307.5 days (range 251-395), all patients (three TM, one SCD) are alive and disease free. MUD HSCT with PTIS, augmented Johns Hopkins conditioning, and PTCy as GvHD prophylaxis is a promising way of treating patients with hemoglobinopathies with low regimen-related toxicity (RRT), no risk of graft failure (GF) and minimal GvHD rates.
26
Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009
Sung‐Yun Pai, Brent R. Logan, Linda M. Griffith et al. · New England Journal of Medicine · 2014 · 771 citations · Full text
Medicine, Hematology, Pediatrics +14
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease
Françoise Bernaudin, Gèrard Socié, Mathieu Kuentz et al. · Blood · 2007 · 502 citations · Full text
Medicine, Hematology, Cell Therapy +12